ESR1 and breast cancer: Ultralow risk tumors were compared to other ER‐positive tumors, including PAM50 molecular subtype luminal A and B tumors, regarding the clinically used breast cancer markers, as well as the expression scores of 19 multigene modules representative of specific biological processes and pathways.